The Department of Internal Medicine II, Faculty of Medicine, University of Yamanashi, Chuo, Japan.
The Department of Neurology, University of Yamanashi, Faculty of Medicine, Chuo, Japan.
Thorac Cancer. 2020 Dec;11(12):3614-3617. doi: 10.1111/1759-7714.13709. Epub 2020 Oct 26.
Immune checkpoint inhibition is associated with a broad spectrum of immune toxicities referred to as immune-related adverse events (irAEs). Myositis is known to be a potentially fatal irAE. Here, we report a case of immune-related myositis after the administration of durvalumab. A 60-year-old man with stage IIIA lung adenocarcinoma was treated with durvalumab after concurrent chemoradiation therapy. After the third dose of durvalumab, his serum CK level was elevated, and soon thereafter myalgia of the proximal muscles and blepharoptosis were observed. We diagnosed immune-related myositis based on the results of pathological examination and initiated systemic corticosteroid therapy. His symptoms then improved and the serum CK level immediately dropped to within a normal range. Clinicians should be aware of possible myositis during the early phase of durvalumab therapy.
免疫检查点抑制与被称为免疫相关不良事件（irAEs）的广泛免疫毒性有关。肌炎是已知的潜在致命的 irAE。在这里，我们报告了一例 durvalumab 给药后发生的免疫相关性肌炎。一名 60 岁男性，患有 IIIA 期肺腺癌，在同步放化疗后接受 durvalumab 治疗。durvalumab 第三剂后，他的血清 CK 水平升高，随后不久出现近端肌肉痛和眼睑下垂。根据病理检查结果，我们诊断为免疫相关性肌炎，并开始全身皮质类固醇治疗。他的症状随后改善，血清 CK 水平立即降至正常范围内。临床医生应在 durvalumab 治疗的早期阶段注意可能出现的肌炎。
